Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19541992 | 0.78 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL16303151 | 0.77 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL2737388 | 0.75 | — | — | |
| SCHEMBL9820230 | 0.74 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL7792046 | 0.72 | NPSR1 (0.53) | — | |
| SCHEMBL20463916 | 0.72 | — | — | |
| SCHEMBL20463912 | 0.72 | — | — | |
| SCHEMBL19766492 | 0.72 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL22404379 | 0.71 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL10111451 | 0.71 | SMN1; SMN2 (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657030-B2 | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof | RHODES TECHNOLOGIES (US) | 2017-05-23 | — | — | US | disclosed |
| US-9388196-B2 | Thiazole derivatives as alpha 7 nAChR modulators | LUPIN LIMITED (IN) | 2016-07-12 | — | — | US | disclosed |
| US-20150291617-A1 | Thiazole Derivatives as Alpha 7 nAChR Modulators | LUPIN LIMITED (IN) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291617-A1 | Thiazole Derivatives as Alpha 7 nAChR Modulators | CHRNA7, CHRM1, CHRM2 | SMN1; SMN2 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.